Human lung tissue and mouse experiments describe a reciprocal signaling loop between damaged alveolar epithelium and senescent fibroblasts. Lung scarring was lower when the team genetically silenced or pharmacologically interrupted parts of the circuit in mice; no therapy or safety protocol was tested in people.
The Communications Biology study examined fibrotic human lung tissue alongside bleomycin-induced mouse models. It focused on damaged alveolar epithelial cells lining the air sacs and on senescent fibroblasts. The findings placed these two cell populations not at opposite ends of a one-way chain, but in a reciprocal signaling circuit that sustains their altered states. Cell-culture experiments also tested the directions of that connection.[1]
According to the paper, sphingosine-1-phosphate released by damaged epithelium promoted cellular senescence in fibroblasts through the S1PR3 receptor. IL-6 produced by senescent fibroblasts then signaled back through the STAT3 pathway in epithelial cells. Human tissue samples showed components of the circuit; causal interventions were performed mainly in mice and cell systems.[1]
Researchers genetically silenced or pharmacologically interrupted different points in the circuit, and lung scarring was lower in mice given bleomycin. That result proposes a targetable biological mechanism, but does not show that a treatment works in people. Dose, adverse effects, disease stage and whether the circuit can be interrupted safely in humans remain unanswered without clinical trials. The mouse model does not remove that limit.[1]
